52,231 Novo Nordisk A/S $NVO Shares Purchased by Hohimer Wealth Management LLC

Hohimer Wealth Management LLC boosted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 59.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 139,895 shares of the company’s stock after buying an additional 52,231 shares during the quarter. Hohimer Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $5,303,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Arrowstreet Capital Limited Partnership acquired a new position in shares of Novo Nordisk A/S in the first quarter worth $287,660,000. State Street Corp raised its stake in shares of Novo Nordisk A/S by 0.6% in the second quarter. State Street Corp now owns 5,869,834 shares of the company’s stock valued at $284,565,000 after acquiring an additional 32,641 shares in the last quarter. Royal Bank of Canada raised its stake in shares of Novo Nordisk A/S by 3.2% in the first quarter. Royal Bank of Canada now owns 4,527,779 shares of the company’s stock valued at $166,396,000 after acquiring an additional 141,376 shares in the last quarter. Envestnet Asset Management Inc. raised its stake in shares of Novo Nordisk A/S by 1.8% in the second quarter. Envestnet Asset Management Inc. now owns 4,031,114 shares of the company’s stock valued at $193,250,000 after acquiring an additional 71,684 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Novo Nordisk A/S by 6.7% in the first quarter. Renaissance Technologies LLC now owns 3,397,121 shares of the company’s stock valued at $124,844,000 after purchasing an additional 213,443 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Growth outlook and Wegovy pill adoption: Novo raised its 2026 outlook as its GLP-1 portfolio continued to grow, with accelerating Wegovy pill adoption and strong patient additions. The company also expects to expand the pill’s availability to more than 20 markets by mid-2027. NVO Q3 Earnings Call Highlights GLP-1 Growth and Raised Outlook Novo Nordisk: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: More evidence for Wegovy beyond obesity: New retrospective real-world studies reported associations between Wegovy 2.4 mg use in adults with MASH and reductions in liver enzymes, weight and blood sugar. The findings could broaden the drug’s potential market, though the study design shows associations rather than proving cause and effect. Novo real-world studies link Wegovy to reductions in liver enzymes, weight, and blood sugar
• Positive Sentiment: Pipeline and valuation support: A report highlighted 12.4% weight loss in a trial of a pipeline drug, while one bullish analyst argued that Novo’s valuation and oral GLP-1 opportunity offer upside. These are potential catalysts, but depend on further clinical and commercial execution. Pipeline drug trial reports 12.4% weight loss
• Neutral Sentiment: Near-term catalysts: Investors are also watching an expected FDA decision and upcoming industry presentations, which could provide direction but add uncertainty until outcomes are known. Novo Nordisk’s Next Act Hinges on Two Clocks
• Negative Sentiment: Profitability and competition remain concerns: Q3 revenue was DKK 79.2 billion, but net income was DKK 16.7 billion, and reports characterized the results as a profit squeeze despite the raised outlook. Generic pressure in Brazil and pricing concerns could constrain margins and future growth. Novo Nordisk Stock Faces Q3 Earnings Profit Squeeze Leadership Reshuffle and Generic Pressure in Brazil

Novo Nordisk A/S Trading Up 0.2%

NYSE NVO opened at $40.37 on Monday. The firm’s fifty day moving average price is $40.58 and its 200 day moving average price is $43.86. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $64.16. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.84 and a quick ratio of 0.64. The company has a market capitalization of $180.26 billion, a price-to-earnings ratio of 10.17, a price-to-earnings-growth ratio of 1.38 and a beta of 0.70.

Analyst Ratings Changes

A number of equities research analysts have issued reports on NVO shares. Cfra lowered Novo Nordisk A/S from a “hold” rating to a “sell” rating and set a $38.00 price target on the stock. in a research report on Tuesday, September 22nd. Barclays reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, September 7th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. BMO Capital Markets set a $40.00 target price on Novo Nordisk A/S and gave the stock a “market perform” rating in a research note on Monday, October 12th. Finally, Jefferies Financial Group reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, September 21st. Five analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and five have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $59.44.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes insulin and other diabetes medicines, as well as obesity treatments such as Wegovy and diabetes treatments such as Ozempic and Rybelsus.

The company also develops medicines for rare blood and endocrine disorders, including hemophilia and growth disorders. Its products are sold in markets around the world.

Novo Nordisk traces its roots to Danish insulin companies founded in the 1920s; the two organizations that became Novo Nordisk merged in 1989.